CT-P72

CT-P72 (also known as ABP-102) is an investigational tetravalent bispecific antibody designed as a HER2 x CD3 T-cell engager for the treatment of HER2-overexpressing cancers. It is engineered to selectively target and kill tumor cells that overexpress the human epidermal growth factor receptor 2 (HER2), while minimizing activity in normal tissues with low HER2 expression. The molecule utilizes a tetravalent IgG1-[L]-scFv format, enabling bivalent binding to HER2 and functionally monovalent engagement of CD3 on T cells. This design aims to optimize tumor selectivity, enhance anti-tumor efficacy, and reduce cytokine-related toxicities commonly seen with earlier T-cell engagers. Preclinical studies have demonstrated potent cytotoxicity against HER2-positive breast and gastric cancer models, reduced cytokine release in non-tumor tissues, improved tolerability at high doses in non-human primates, and superior tumor suppression compared to benchmark bispecific antibodies such as runimotamab biosimilars. CT-P72 is being co-developed by Abpro Holdings and Celltrion for multiple solid tumors including breast cancer, gastric cancer, pancreatic cancer, colorectal cancer, and other HER2-positive malignancies[1][3][5][7].

Other names

ABP-102ABP102ABP 102